CytoMed Therapeutics Ltd
corporate_fare Company Profile
CytoMed Therapeutics Ltd (NASDAQ:GDTC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for GDTC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-13, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for GDTC spans SCHEDULE 13D/A, 6-K, 4, 144.
Recent high-impact activity:
- Chairman Choo Chee Kong Buys $60.5K More CytoMed Shares, Stake Rises to 24.92%
- CytoMed Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice
- CytoMed Flags Going Concern, Books S$1M Director Loan in H1 2026 Report
- Director and 10% Owner Choo Chee Kong Buys $300K More of CytoMed Therapeutics
- Chairman Offers to Buy Shares, Invests $250K in Subsidiary R&D Amidst Financial Challenges
Financial Snapshot
Short Interest & Short Volume
1.81 days to coverFINRA reported short interest of 17,603 shares in GDTC as of the October 30, 2026 settlement, a 9.0% decrease from the prior period — about 1.8 days to cover at its recent average daily volume. On November 20, 2026, 25.1% of GDTC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
GDTC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.